川寧生物(301301.SZ):自研究院成立以來,目前已累計交付合成生物學品種近十個
格隆匯10月23日丨川寧生物(301301.SZ)在投資者關係活動上表示,自研究院成立以來,目前已累計交付合成生物學品種近十個,其中包含:紅沒藥醇、五羥基色氨酸、麥角硫因、肌醇、角鯊烷、角鯊烯、依克多因、植物鞘氨醇等產品。目前各個產品的產業化進度如下:其中紅沒藥醇、5-羥基色氨酸、麥角硫因、肌醇已進入生產階段;角鯊烷、角鯊烯、依克多因已完成中試,植物鞘胺醇小試已完成,已進入中試階段。合成生物學生產基地一期項目主體已經完成,政府配套設施熱電聯產項目預計今年年底完成,現在已經交付的產品會在熱電聯產完後後逐步滿產。疆寧生物的二期項目預計明年進行規劃設計。主要產品計劃大噸位的飼料添加劑、氨基酸類、化粧品原料等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.